| dc.identifier.citation | Abera, Julian S., 2015. Incidence of Antituberculosis Drug Induced Hepatotoxicity and Associated Risk Factor Among Tuberculosis Patients in Dawro Zone, South Ethiopia: A Cohort Study. Abera W, Cheneke W, Abebe G. Incidence of antituberculosis drug induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. Int J Mycobacteriology. 2016;5(1):14–20 Ali A, Belachew T, Yami A, Ayen W. Anti-Tuberculosis Drug Induced Hepatotoxicity among TB / HIV Co-Infected Patients at Jimma University Hospital, Ethiopia : Nested Case-Control Study. PloS One. 2013;8(5):1–8. Anand, Anil C., & Hospitals, Indraprastha Apollo. (2015). Risk Factors of Hepatotoxicity During Anti-tuberculosis. Medical Journal Armed Forces India. (February), 45–49. Amanda, G. 2018. Peran Aerosol M. tuberculosis pada Penyebaran Infeksi Tuberkulosis. Cerminan Dunia Kedokteran, 63-65. Amiruddin, Ridwan. 2006. Faktor Resiko Kegagalan Konversi Pada Penderita TB Paru BTA Positif di Kota Ambon Tahun 2006. Dinas kesehatan Kota Ambon. Badie, BM, M. 2012. Comparing Radiological Features of Pulmonary Tuberculosis with and without HIV Infection. Jurnal AIDS Clinic Res, 3 (10), 1-3. Bang, E. 2009. Tuberkulosis, httpps / medicine / medscape.com / article, diakses tanggal 05 Desember 2020. Bayupurnama, Putut. 2006. Hepatoksisitas karena Obat dalam Buku Ajar Ilmu. Jakarta : Balai Penerbit FK UI. Borzakova, S.N.dkk. 2013. Viral and Drug-Induced Liver Damage in Children with Tuberculosis: Prevalence, Clinical Features. Eksp Klin Gastroenterol, 1: 38-43. Bustan, M.N. 2007. Epidemiologi Penyakit Tidak Menular. Edisi II. Jakarta: Rineka Cipta. Castrighini., Carolina., de.C.C.; Renata,K.R.; Neves., S.A.L.;Galvao., G.T.M., and Elucir,G. Crofton & John, (2000). Tuberkulosis Kinik, Widya Medika, Jakarta (2013). Epidemiological Profile of HIV/Tuberculosis Co-infection in a City the State of Sao Paulo Brazil. Volume 5, hal 119-122. Crofton & John, (2000). Tuberkulosis Kinik, Widya Medika, Jakarta. Dwisarwa S & Nurlaela, (2011). Merokok dan Tuberkuosis Paru (Studi Kasus do RS Margono Soekardjo Purwokerto) Danusantoso, H. 2012, Buku Saku Ilmu Penyakit Paru, Hipokrates, Jakarta. Depkes, RI., 2011. TBC Masalah Kesehatan Dunia. Jakarta: BPPSDMK Desy,2012. Risk Factor of Tuberculosis Coinfection In Hiv/Aids Patient In Dr. Kariadi Hospital Semarang.Faculty of Medicine Diponegoro University. Dessy, et.,all. 2012. Analisis Kejadian Efek Samping Obat Pada Pasien Tb/Hiv Ko-Infeksi Di Rumah Sakitumum Persahabatan Jakarta. Jurnal ilmiah indonesia.Vol. 6, No. 1, Januari 2021. Devarbhavi, Harshad. (2012). An update on drug-induced liver injury. Journal of Clinical and Experimental Hepatology, 2(3), 247–259 Devarbhavi, Antituberculous drug-induced liver injury: Current perspective, Trop. Gastroenterol. 32 (2011) 167–174 Dienstag, LJ, Isselbacher KJ. 2008. Toxic and drug induced hepatitis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. United States of America: McGraw Hill Company, 49-54. Dipiro, J.T., et al. 2005. Pharmacotherapy Handbook. Sixth edition. The Mc.Graw Hill. Company. USA. hal. 1891-1939. Essig, M. G. 2008. Alanine Aminotransferase, http: www.webmd.com, diakses tanggal 05 Desember 2020. Getahun, H, et al, 2010. HIV Infection-Association Tuberculosis: The Epidemiology and the Response. Clinical Infectious Diseases, 50, S201-S207 http://dx.doi.org/10.1086/651492. Gunawan, Sulistia Gan dkk. 2011. Farmakologi dan Terapi Edisi 5. Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia. Helmia dan lulu manase, 2004. Tuberkulosis In alsagaff hood, (Eds), Buku ajar ilmu penyakit paru: Surabaya. https://www.rsudaws.co.id/uploads/DOWNLOAD/Profil%20RSUD%20AWS%202017. Profil rumah sakit,2017. Irianti, Dr. Rer. Net. T, Kuswandi, Yasin, Dr. N. M, Kusumaningtyas, R. A. 2016. Mengenal Anti-Tuberkulosis: Yogyakarta Iskandar. Hubungan karakteristik penderita, lingkungan fisik, rumah dan wilayah dengan kejadian tuberkulosis paru di Kabupaten Aceh Tenggara tahun 2009 (tesis). Medan: Fakultas Kesehatan Masyarakat Universitas Sumatera Utara; 2009. Jasmer,R.M., et.,al. 2002. Short-Course Rifampin and Pyrazinamide Company Latent Tuberculosis Infection: A Multicenter Clinical Trial. Annals. of. Int Med, 137: 640. Javadi, G. Shalviri, K. Gholami, et al, Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity, and risk factors, Pharmacoepidemiol, Drug Saf. 16 (2007) 1104–1110. Jessica raphaela., dkk. 2019. Prevalensi dan Gambaran Umum Drug-Induced Liver Injury Akibat Obat Anti Tuberkulosis pada Pasien Tuberkulosis RSUP Sanglah Denpasar Periode Agustus 2016 –Juli 2017 Jurnal medika Udayana: Vol.8 No.9. Kar P. 2012. Tuberculosis and Liver Disease: management issues. Tropical Gastroenterology, 6(4):102-106. Kato, H. et al. 2013. Risk factors for liver injury with an elevated serum bilirubin concentration caused by antituberculous drugs, nternal medicine. The Japanese Society of Internal Medicine, 52(19), pp. 2209–2214. Kementerian Kesehatan Republik Indonesia, 2014. Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman nasional pengendalian tuberculosis. Kementerian Kesehatan Republik Indonesia, 2015. Rencana Strategis Kementerian Kesehatan Tahun 2015-2019, Jakarta: Indonesia. Kemenkes RI, 2016. Tuberkulosis Temukan Obati Sampai Sembuh. Jakarta: Pusat Data dan Informasi Kementrian RI. Kisembo HN, et.al., 2012. Chest radiographic dinding of pulmonary tuberkulosis Ni severely immunocompromised patients Alt human immunodeficiency virus. The British Journal of Radiology, June130-40 Koda – Kimble, M.A., and Young, L.Y., 2005. Tuberculosis, in Applied Therapeutics. The clinical drugs, Seventh Ed., Lippincot Williams and Wilkens: Philadelphia. Kosasih, E. N. and Kosasih, A. S, 2008. Tafsiran hasil pemeriksaan laboratorium klinik. Medical Laboratory Technology: Tangerang 3(2), pp. 42–46. Kurniawati, E., 2013. Aplikasi Teori Health Belief Model Dalam Pencegahan Keputihan Patologis. Jurnal Promkes, Vol. 2, No. 2 Desember 2014: 117–127. Kumar pramod avti., dkk. Smokeless tobacco impairs the antioxidant denese in liver, lung and kidney of rats.Oxford. 2005. Latief M, Dar WR, Sofi N, Dar IA, Kasana B, Hussain M, dkk. Novel risk factors and early detection of anti-tubercular treatment induced liver injury. Indian J Tuberc. 2017;64(1):26-32. Lee, Schiodt FV. 2003. Drug induced liver disease. In: Yamada T, editor. Texbook of Gastroenterology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, p.2352-65. Lee, A., dkk., 2005, Novel Mutations in ndh in Isoniazid Resistant Mycobacterium Tuberculosis Isolates, Antimicrob Agents Chemother, 45 (9), 2157. Luthariana, Lies., 2017. Faktor Risiko Terjadinya Hepatotoksisitas Imbas Obat Anti tuberkulosis pada Pasien HIV/AIDS. Jurnal Penyakit Dalam Indonesia. Vol 4: 23-24. Loubser, Shayne et al. 2010. Tuberculosis Drugs-First Line. http://immunopaedia.org/index.php?id=260&L=0&key=0.Diakses Desember 2020. Maulidya YN, Redjeki ES, Fanani E. 2017. Faktor Yang Mempengaruhi Keberhasilan Pengobatan Tuberkulosis (TB) Paru Pada Pasien Pasca Pengobatan Di Puskesmas Dinoyo Kota Malang. Jurnal Preventia, hal.2 Maria de Fátima et.,all. 2012 Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis Hospital das Clínicas de Pernambuco, Recife, Brasil.Cad. Saúde Pública, Rio de Janeiro, 28(4):698-708, Marzuki OA, Fauzi AR, Ayoub S, dkk. Prevalence and risk factors of anti-tuberculous drug induced hepatitis in Malaysia. Singapore Med J. 2008;49(9):688–693. Makonnen, daniel., 2015.TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study.Department of Medical Microbiology, Immunology and Parasitology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia : BMC Res Notes (2015) 8:666 Mulyadi. 2011. Profil Penderita Tuberculosis Paru di Pesisir Pantai Aceh Barat Daya (Kajian di Puskesmas Blangpidie). J Respir Indo. Nuraini, agustin., 2016.Analisis faktor klinik dan pengobatan yang mempengaruhi keberhasilan terapi Tuberkulosis pada pasien koinfeksi HIV–TB di klinik VCT RSD dr. Soebandi Jember,Farmasi,Universitas : Jember. Naga,S.Ilmi Penyakit Dalam.Yogyakarta :Diva Press:2012. Natalie, Josephine, Kholis, Fathur Nur, &Ngestiningsih, Dwi. (2016). Jenis–Jenis Efek Samping Pengobatan Oat Dan Art Pada Pasien Dengan Koinfeksi Tb /Hiv Di Rsup Dr. Kariadi.5(4), 1134–1145. Ningrum, Vitarani D. A., Megasari, Arnia., Hanifah, Suci., 2010. Hepatotoksisitas pada Pengobatan Tuberkulosis di RSUD Tangerang-Indonesia. Jurnal Ilmiah Farmasi. Notoatmodjo,S. 2012. Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta. Notoatmodjo., 2010, Metode Penelitian Kesehatan, Rineke Cipta, Jakarta. Noor, N. Epidemiologi. Jakarta: Rineka Cipta; 2008. Panjaitan F. Karakteristik Penderita Tuberkulosis Paru Dewasa rawat Inap di Rumah Sakit Umum dr. Soedarso Pontianak Periode SeptemberNovember 2010. Fakultas Kedokteran Universitas Tanjungpura. 2012. (Skripsi). Pukenyte E, et al. 2007. Incidence of and risk factors for severe liver toxicity in HIVinfected patients in anti-tuberculosis treatment. Int J Tuberc Lung Dis, 11(1):78-84. Pratiwi, elsa,P., 2018. Efek Samping Obat Antituberkulosis Kategori I dan II Pasien Tuberkolosis Paru Dewasa di Rumah Sakit Hasan Sadikin.Bandung,Universitas Kedokteran Padjajaran. Rahayu, Ani. (2018). Analisis Efektifitas Biaya Terapi Anti hipertensi Kombinasi Pada Pasien Hipertensi Di Ruang Rawat Inap RSUD DR. Soekardjo Tasikmalaya. STIKes BTH Tasikmalaya. R. Shakya, BS Rao, B. Shrestha, Evaluasi faktor risiko untuk hepatotoksisitas yang diinduksi obat antituberkulosis pada populasi Nepal, Kathmandu Univ. Med. J.2 (2006) 2–4. Rahmawati F, R. Handayani, V. Gosal, Kajian Retrospektif Interaksi Obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta, Majalah Farmasi Indonesia, 2006;17(4):177-83. Rafiq S, Iqbal T, Jamil A, Khan HF. Pharmacokinetic studies of indoprofen in healthy volunteers and in patients. International Journal of Agriculture & Biology.2015. Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3(1):37–49. Resky hevia., L.2017.Gambaran Kadar Enzim Transaminase Pada Pasien Tuberkulosis Yang Mendapat Terapi Obat Anti Tuberkulosis Di Unit Pengobatan Penyakit Paru-Paru Provinsi Kalimantan Barat.Pendidikan Dokter, Fakultas Kedokteran, Universitas Tanjungpura, Pontianak, Kalimantan Barat. Rian, 2010. Pengaruh Efek Samping Obat Anti Tuberkulosis Terhadap Kejadian Default di Rumah Sakit Islam Pondok Kopi Jakarta Timur Januari 2008 – Mei 2010. Tesis, Dipublikasikan, Jakarta, Universitas Indonesia. Sacher RA, McPherson RA. 2004. Uji Fungsi Hati. Tinjauan Klinis Hasil Pemeriksaan Laboratorium, Edisi ke-11, Jakarta: Penerbit Buku Kedokteran EGC. Saukkonen JJ, et al. 2006. An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, vol. 174. Saputri, A.S.A.R. 2015. Faktor-Faktor Koinfeksi TB Paru pada Pasien HIV/AIDS di Balai Kesehatan Paru Masyarakat (BKPM) Semarang Tahun 2015. Skripsi. Universitas Negeri Semarang. Sakamoto, K. 2012. The Pathology of Mycobacterium tuberculosis Infection. Journal of Veterinary Pathology, 49 (3): 423, diunduh 18 Desember 2020. Samuel Pola Karta Sembiring, Indonesia bebas tuberkulosis.2019. suka bumi: Jawa barat Hal.111 Savita Mishra, Vidhu Aeri and Deepshikha Pande Katare. (2014). Hepatoprotektor protective Medication for Liver Injury. World Journal and Pharmaceutical Sciences, 5(3), 891–932. Sharifzadeh, M. Rasoulinejad, F. Valipour, et al, Evaluation of patient-related factors associated with causality, preventability, predictability, and severity of hepatotoxicity during antituberculosis treatment, Pharmacol. Res. 51 (2005) 353–358. Sherlock, S. & Dooley, J., 2002, Diseases of the Liver and Biliary System. Edisi ke 11. London: Blackwell Publishing Singla R., Khan N., Al-Sharif N., Ai-Sayegh M.O., Shaikh M.A., Osman M.M. 2010. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. Int J Tuberc Lung Dis. 10: 74-79. Sudarsono, 2002. Penatalaksanaan tuberkulosis paru dalam strategis DOTS in palilingan J.F., (eds), global management of tuberculosis reach an Indonesian Health for all in the year 2010: Surabaya. Soo Hui L, Lee Cheng H, Loong Hui T, Mohamad N, Yazid A, Lay Harn G. Antituberculosis. Webmed Central Pharmaceutical Sciences.2011. Taha M, 2011. Risk factors of active tuberculosis in people living with HIV/AIDS in Southwest Ethiopia: A case control study. Toastmann et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology. 2007; 10:192-202 Wannamethee, 2001. Smoking as a Modififiable Risk Factor for Type 2 Diabetes in Middle-Aged Men, Psychosocial Research. Volume 24, Number 9 WHO, 2015. Tuberculosis control in the southeast asia region: annual report 2015 Geneva: World Health Organization. World Health Organization (WHO), 2015. Global Tuberculosis Report. Geneva: WHO. Wijaya, A. S., & Putri, Y. M. 2013. KMB 1 Keperawatan Medikal Bedah Keperawatan Dewasa Teori Dan Contoh Askep. Yogyakarta: Nuha Medika. Wong, R. J. et al. 2007. Neonatal Jaundice: Bilirubin Physiology and Clinical Chemistry The online version of this article, along with updated information and services, is located on the World Wide Web at, doi: 10.1542/neo.8-2-e. Zeleke,Abebe,Drug-inducedhepatotoxicity among TB/ HIV co-infected patients in a referral hospital, Ethiopia : Department of Pharmacy.Wollo University.2020: 13(2). | id_ID |
